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Background: Breast tissue is among the most sensitive tissues to the carcinogenic actions of ionizing radiation
and epidemiological studies have linked radiation exposure to breast cancer. Currently, molecular understanding of
radiation carcinogenesis in mammary gland is hindered due to the scarcity of in vivo long-term follow up data.
We undertook this study to delineate radiation-induced persistent alterations in gene expression in mouse
mammary glands 2-month after radiation exposure.
Methods: Six to eight week old female C57BL/6J mice were exposed to 2 Gy of whole body γ radiation and
mammary glands were surgically removed 2-month after radiation. RNA was isolated and microarray hybridization
performed for gene expression analysis. Ingenuity Pathway Analysis (IPA) was used for biological interpretation of
microarray data. Real time quantitative PCR was performed on selected genes to confirm the microarray data.
Results: Compared to untreated controls, the mRNA levels of a total of 737 genes were significantly (p<0.05)
perturbed above 2-fold of control. More genes (493 genes; 67%) were upregulated than the number of
downregulated genes (244 genes; 33%). Functional analysis of the upregulated genes mapped to cell proliferation
and cancer related canonical pathways such as ‘ERK/MAPK signaling’, ‘CDK5 signaling’, and ‘14-3-3-mediated
signaling’. We also observed upregulation of breast cancer related canonical pathways such as ‘breast cancer
regulation by Stathmin1’, and ‘HER-2 signaling in breast cancer’ in IPA. Interestingly, the downregulated genes
mapped to fewer canonical pathways involved in cell proliferation. We also observed that a number of genes
with tumor suppressor function (GPRC5A, ELF1, NAB2, Sema4D, ACPP, MAP2, RUNX1) persistently remained
downregulated in response to radiation exposure. Results from qRT-PCR on five selected differentially expressed
genes confirmed microarray data. The PCR data on PPP4c, ELF1, MAPK12, PLCG1, and E2F6 showed similar trend
in up and downregulation as has been observed with the microarray.
Conclusions: Exposure to a clinically relevant radiation dose led to long-term activation of mammary gland
genes involved in proliferative and metabolic pathways, which are known to have roles in carcinogenesis.
When considered along with downregulation of a number of tumor suppressor genes, our study has implications
for breast cancer initiation and progression after therapeutic radiation exposure.
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We know from epidemiological studies that exposure to
ionizing radiation (IR) is one of the major risk factors
for breast cancer especially if exposure occurs at a young
age [1,2]. Exposure to radiation, which is increasingly
used in diagnostic and therapeutic interventions, is
unavoidable and is predicted to pose carcinogenic risk
[3,4]. Radiation induces a myriad of damage to bio-
molecules including DNA and the carcinogenic potential
of radiation has been attributed to alterations in the
expression of genes, which could induce proliferation
and provide survival advantage to cells. Changes in gene
expression in response to radiation have been reported
to vary depending on the dose and the tissue exposed;
and, there are significant differences in acute and
delayed responses to IR exposure [5]. Delayed effects
of IR on gene expression are not only associated with
cancer initiation and promotion in normal cells but are
also known to play a critical role in the development of
resistance to therapy in cancer cells [5]. Therefore, radi-
ation treatment of breast cancer has on the one hand
the potential for cancer recurrence and on the other the
risk for developing new cancer in the contralateral breast
[4]. Despite the fact that radiation exposure causes per-
sistent changes in gene expression, data on radiation-
induced long-term alterations in gene expression in
mammary tissues are of limited availability. Furthermore,
there are no reports in the literature of long-term micro-
array-based studies of changes in mouse mammary
gland gene expression after exposure to radiation doses
relevant to therapeutic procedures. Considering the car-
cinogenic potential of radiation exposure to mammary
glands, it is important to understand how radiation
modulates long-term gene expression changes and how
these changes relate to oncogenic signaling pathways
known to be involved in breast cancer initiation and
progression. Therefore, the goals of this study were to
characterize persistent transcriptomic alterations and
explore how these alterations relate to biological func-
tions in whole body exposed 6 to 8 week old female
C57BL6/J mouse mammary glands 2 months after expo-
sure to 2 Gy γ radiation.
Methods
Mice and irradiation
Mice (C57BL/6J, female, 6-8 week old) were purchased
from Jackson Laboratories (Bar Harbor, ME, USA) and
were housed at the Georgetown University’s (GU) ani-
mal facility. All the animal procedures were performed
as per protocol approved by GU Animal Care and Use
Committee (GUACUC). Mice were placed in a circular
pie shaped, well-ventilated plastic mouse holder, the
mouse holder with mice was positioned on a rotating
turntable inside the irradiator, and mice were exposed toγ radiation using a 137Cs source. Radiation dose was
delivered at a rate of 1 Gy/min and a total dose of 2 Gy
was delivered to the whole body and the control groups
were sham irradiated. After irradiation mice were
returned to their home cage, and monitored regularly.
RNA isolation
Mice were euthanized by asphyxiation using CO2 as per
GUACUC approved protocol and mammary glands were
surgically removed 2 month after radiation exposure
for RNA extraction. For RNA extraction, we used no. 4
mammary gland from the left side of each mouse and
four such mice were used in each experimental group.
Total RNA was isolated with Trizol reagent (Invitrogen,
Carlsbad, CA) from fresh or flash frozen mammary
glands followed by purification over an RNeasy column
according to the manufacturer’s instructions (Qiagen,
Germantown, MD) and stored at -80°C for further
use. RNA quality was determined using a Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
Microarray analysis
Cy3-labeled cRNA was generated from 300 ng total
RNA using Agilent’s Low RNA Input Linear Amplifica-
tion PLUS kit. Cy3-labeled cRNA (1.65 μg) was hybri-
dized to Agilent’s Mouse Whole Genome arrays
(G4122F) with Agilent’s GEx Hybridization HI-RPM
Buffer. The samples were hybridized for 16 hours in a
rotisserie hybridization oven (G2545A, Agilent Tech-
nologies, Santa Clara, CA, USA), then washed with Agi-
lent’s gene expression wash buffers and scanned with an
Agilent DNA Microarray Scanner 2505A in an ozone
hood. Subsequent image analysis, data extraction, and
background corrections were performed with Agilent’s
Feature Extraction Software 9.1. Extracted data were
then analyzed using GeneSpring GX 10.0 (Agilent Tech-
nologies) to identify genes that had significantly changed
expression between control and the irradiated group.
Although small sample size (3 to 5 biological replicates)
conventionally used in microarray experiments has its
limitations, the large data sets used in comparative ana-
lysis provide enough statistical power to derive biologic-
ally meaningful inferences from the results (discussed in
Prolla, 2002 [6]). Genes considered significantly (p<0.05,
t-test with Benjamini-Hochberg correction [7]) and differ-
entially (fold change ≥2.0) regulated were listed separately.
Pathway analysis for biological functions
Significantly perturbed gene lists generated from micro-
array analysis were uploaded onto Ingenuity Pathway
Analysis (IPA, Ingenuity Systems Inc., Redwood City,
CA, USA) for assignment of biological function as
well as for identifying perturbed signal transduction
networks. IPA combines the uploaded data and the
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information from available literature, to identify bio-
logical networks that are significantly over-represented
in the gene expression data. Right-tailed Fisher's exact
test is applied to determine the level of significance for
each network and the p-value is displayed as score,
which is the negative log of that p-value. A score of 8
indicates that there is a 1 in 108 chance that the focus
genes are together in a network due to random chance
alone. Furthermore, IPA uses a built-in library to identify
association between the uploaded genes with the canon-
ical pathways present in the knowledge base. In addition
to providing a significance score, IPA also calculates the
number of genes within a dataset that are present in each
significantly perturbed pathway.
Quantitative real time PCR (qRT-PCR)
For confirmation of microarray data by qRT-PCR, cDNA
was generated from 1.5 μg RNA using the RT2 First
Strand Kit as per recommendation (SA Biosciences,
Frederick, MD, USA). Primers for PPP4c (protein phos-
phatase 4, catalytic subunit; Cat# PPM28940A), MAPK12
(mitogen-activated protein kinase 12; Cat#PPM04541C),
PLCG1 (phospholipase C, gamma 1; Cat#PPM004022B),
and β-actin (Cat# PPM02945A) were obtained from SA
Biosciences. Primers for E2F6 (Forward primer: 5’-GAT-
GGCATCGAACTGGTGGAA-3’; reverse primer: 5’-CC-
CCAAAGTTGTTCAGGTCAG-3’ [8]), and ELF1 (Forward
primer: 5’-TGTCCAACAGAACGACCTAGT-3’; reverse
primer: 5’ CACACAAGCTAGACCAGCATAA-3’ [8]) were
obtained from Eurofins MWG Operon (Huntsville, AL,
USA). Primer for NFkβ, which is the nodal molecule of
the top scoring molecular pathway network identified from
the microarray data set by IPA, was also obtained from
Eurofins MWG Operon (Forward primer: 5’-AGCACATA-
GATGAACTCCG-3’; reverse primer: 5’- CTGTAAAGCT-
GAGTTTGCG-3’ [9]). Using the RT2 SYBR Green/
Fluorescein qPCR Master mix (SA Biosciences) qRT-PCR
was performed on an ABI 7900HT (Applied Biosystems,
Carlsbad, CA, USA) platform with temperature settings:
95°C (denaturation) for 10 min and then 40 cycles of
95°C for 15 sec, annealing/extension at 60°C for 1 min.
The fold change was calculated using β-actin as an
endogenous control following the comparative Ct (ΔΔCt)
method as described previously [10]. Results were
expressed relative to control samples, and three biological
replicates were used in each experimental group. The
error bar represents standard error of mean (SEM).
Results
Greater number of genes showed persistent upregulation
following radiation exposure
Global analysis of microarray data indicated that com-
pared to control the mRNA level of a total of 737 genesremained perturbed 2-month after exposure to 2 Gy of γ
radiation. While 67% (493 genes) of the genes were
upregulated, we observed that only 33% (244 genes) of
the genes were downregulated (Figure 1A). When we
assessed the scale of variation in the significantly per-
turbed genes’ list (relative to control p<0.05 and above
2-fold), the majority of the upregulated fold changes
were between 1 and 3 fold and the majority of the down-
regulated fold changes were between 1 and 2 fold
(Figure 1B).
Quantitative real time PCR confirmation of
microarray data
We performed qRT-PCR on five selected differentially
expressed genes to confirm microarray data. The PCR
data on PPP4c, ELF1, MAPK12, PLCG1, and E2F6
exhibited a trend similar to our microarray measure-
ments (Figure 2). Compared to control, PPP4c (fold
change -3.14 ± 0.41 standard error of mean (SEM);
p<0.001; microarray fold change -1.54) and ELF1 (fold
change -2.49±0.55; p<0.003; microarray fold change
-1.78) was downregulated and were consistent with
microarray results. Also, in agreement with our micro-
array data, we observed upregulation of MAPK12 (2.47
±0.47; p<0.02; microarray fold change 1.85), PLCG1
(3.28±0.76; p<0.02; microarray fold change 1.96), and
E2F6 (1.69±0.28; p<0.04; microarray fold change 1.7)
expression. We also performed qRT-PCR of NFkβ,
which is the nodal molecule of the highest scoring
molecular network obtained from IPA (fold change
1.65 ± 0.12; p<0.03 in γ irradiated samples compared to
control; Figure 2).Pathway analysis shows upregulation of metabolic and
proliferative pathways
To identify which pathways were perturbed 2 months
after radiation exposure, we subjected the up and down-
regulated gene sets to IPA. The results of the analysis
associating altered genes to specific canonical pathways
are presented in Table 1 (Upregulated) and 2 (Down-
regulated), and also in Figure 3A (Upregulated) and B
(Downregulated). While the upregulated gene sets were
significantly associated with 37 canonical pathways
(35 presented in Table 1) with a p value cutoff of 0.05
(corresponds to -log p value of 1.3), the downregulated
genes were mapped to 7 pathways with similar level of
significance (Table 2). Most of the upregulated pathways
were involved in cellular growth and proliferation
including ‘ERK/MAPK signaling’, ‘14-3-3-mediated sig-
naling’, ‘endothelin-1 Signaling’, ‘protein kinase A sig-
naling’, ‘AMPK signaling’, and ‘corticotropin releasing
hormone signaling’. At least two pathways related to
breast cancer – ‘breast cancer regulation by Stathmin1’
Figure 1 Exposure to ionizing radiation results in persistent perturbations of mammary gland gene expression. A) Total number of
transcripts perturbed 2-month after exposure to 2 Gy of whole body γ radiation. About 67% of the transcriptomes were upregulated and 33%
remained downregulated. B) Transcripts significantly modulated relative to control (p<0.05 and more than 2-fold change) were plotted showing
fold change distribution. Most of the upregulated genes were between 1 and 3 fold and the downregulated genes were clustered mostly
between -1 and -2 fold.
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to be upregulated. Metabolism was, also, a common
theme among the upregulated pathways with the highest
scoring pathways being ‘oxidative phosphorylation’ and
‘mitochondrial dysfunction’. Additionally, ‘glycolysis/glu-
coneogenesis’, ‘inositol metabolism’, and ‘ubiquinone bio-
synthesis’ were in the top 10 upregulated pathways. The
downregulated gene sets were mapped to fewer canon-
ical pathways none of which are associated with cellular
metabolism or proliferation except for the ‘G-protein
coupled receptor signaling’. All the up and downregu-
lated canonical pathways obtained from the IPA are
presented in Additional files 1 (Upregulated) and 2
(Downregulated) for reference.
When we used IPA to map the sets of perturbed genes
to gene interaction networks in the Ingenuity PathwaysFigure 2 Confirmation of microarray data by PCR analysis. Results of P
(MAPK12, PLCG1, and E2F6) genes showed a trend similar to the microarray fKnowledge Base (IPKB), the upregulated genes were
mapped to a total of 23 networks, whereas the downre-
gulated genes were associated with 13 signaling net-
works. Networks with score ≥8 for the up and
downregulated genes are presented in Tables 3 (12 upre-
gulated networks had a score of ≥8) and 4 (4 downregu-
lated networks had a score of ≥8), respectively, and
genes from the microarray dataset are identified in bold.
Graphical presentation of the up and downregulated
networks with a score of ≥8 demonstrates long-term
signaling pathway alterations after radiation exposure
(Figures 4, 5, 6, 7, 8, 9, 10 and 11). The functions related
to upregulated networks ranges from cell death, cell
cycle, cell growth and development to carbohydrate and
lipid metabolism. Among the upregulated genes, the net-
work with highest score has NFkβ as the nodal moleculeCR analysis of 2 downregulated (PPP4C, and ELF1) and 3 upregulated
old change. NFkβ is the nodal molecule of the top upregulated network.
Table 1 Significant upregulation of pathways involved in cell proliferation, metabolism and breast cancer
Ingenuity Canonical Pathways -log(p-value) Molecules
Oxidative phosphorylation 4.16 ATP6V0E2, NDUFC1, COX6B1, NDUFS8, COX10, COX5A, NDUFS6,
NDUFA12, COX7A1, ATP5G3
Mitochondrial dysfunction 4.06 COX6B1, NDUFS8, COX10, CPT1B, COX5A, TRAK1, NDUFS6,
NDUFA12, MAPK12, COX7A1
Breast cancer regulation by Stathmin1 3.81 PPP1R14C, PIK3C2B, E2F6, ADCY2, PRKCQ, CAMK2A, TUBA8,
PPM1L, PPP2R5B, TUBA4A, PPP1R3A, TUBA3C/TUBA3D
ERK/MAPK signaling 2.81 PLA2G4E, PPP1R14C, PIK3C2B, TLN2, PLA2G12A, HSPB2, PPM1L,
PPP2R5B, PLCG1, PPP1R3A
Cardiac β-adrenergic signaling 2.56 PPP1R14C, ADCY2, PPM1L, PPP2R5B, PDE4A, AKAP6, PPP1R3A, PDE4D
Glycolysis/gluconeogenesis 2.47 PGK1, PGM1, ALDOA, TPI1, Gapdh (includes others), LDHB
Inositol metabolism 2.46 ALDOA, TPI1
Ubiquinone biosynthesis 2.46 NDUFC1, NDUFS8, UFSP1, NDUFS6, NDUFA12
14-3-3-mediated signaling 2.44 PIK3C2B, PRKCQ, TUBA8, TUBA4A, PLCG1, TUBA3C/TUBA3D, MAPK12
Aldosterone signaling in epithelial cells 2.16 PIK3C2B, SACS, PRKCQ, HSPA1L, DNAJC27, HSPB2, PLCG1, DNAJB5
Production of nitric oxide and reactive oxygen species
in macrophages
2.14 PPP1R14C, PIK3C2B, PRKCQ, PPM1L, PPP2R5B, PLCG1, PPP1R3A, MAPK12
Fc epsilon RI signaling 2.03 PLA2G4E, PIK3C2B, PRKCQ, PLA2G12A, PLCG1, MAPK12
Endothelin-1 signaling 2.03 PLA2G4E, PIK3C2B, ADCY2, PRKCQ, PLA2G12A, GNAO1, PLCG1, MAPK12
Dopamine receptor signaling 1.96 PPP1R14C, ADCY2, PPM1L, PPP2R5B, PPP1R3A
CCR3 signaling in eosinophils 1.83 PLA2G4E, PIK3C2B, PRKCQ, PLA2G12A, CFL2, MAPK12
Type II diabetes mellitus signaling 1.81 PIK3C2B, RKCQ, PRKAB2, MAPK12, ADIPOR1, KCNJ11
Thrombopoietin signaling 1.75 PIK3C2B, THPO, PRKCQ, PLCG1
CTLA4 signaling in cytotoxic T lymphocytes 1.73 PIK3C2B, AP1S2, PPM1L, PPP2R5B, PLCG1
CDK5 signaling 1.71 PPP1R14C, ADCY2, PPM1L, PPP2R5B, PPP1R3A
TR/RXR activation 1.69 PIK3C2B, RXRG, SLC16A3, UCP1, PPARGC1A
Protein kinase A signaling 1.68 PPP1R14C, ADCY2, PRKCQ, CAMK2A, HIST1H1A, PDE4A, PLCG1, AKAP6,
PPP1R3A, TTN, PDE4D
Synaptic long term depression 1.65 PLA2G4E, PRKCQ, PLA2G12A, PPM1L, GNAO1, PPP2R5B
Role of MAPK signaling in the pathogenesis of influenza 1.62 PLA2G4E, PLA2G12A, MAPK12, RABGEF1
Cell cycle regulation by BTG family proteins 1.58 E2F6, PPM1L, PPP2R5B
MIF regulation of innate immunity 1.52 PLA2G4E, PLA2G12A, MAPK12
glioma signaling 1.52 PIK3C2B, E2F6, PRKCQ, CAMK2A, PLCG1
Phenylalanine, tyrosine and tryptophan biosynthesis 1.50 GOT1, GOT2
AMPK signaling 1.48 PIK3C2B, PRKAB2, CPT1B, PPM1L, PPP2R5B, MAPK12
Melatonin signaling 1.46 PRKCQ, CAMK2A, GNAO1, PLCG1
Macropinocytosis signaling 1.44 PIK3C2B, PRKCQ, PLCG1, ITGB6
Cysteine metabolism 1.43 GOT1, GOT2, LDHB
ILK signaling 1.40 PIK3C2B, CFL2, PPM1L, PPP2R5B, MAPK12, ITGB6, MYH1
Protein ubiquitination pathway 1.38 SACS, USP15, HSPA1L, USP13, UBE2B, DNAJC27, HSPB2, USP2, DNAJB5
Corticotropin releasing hormone Signaling 1.32 ADCY2, PRKCQ, GNAO1, PLCG1, MAPK12
HER-2 signaling in breast cancer 1.30 PIK3C2B, PRKCQ, PLCG1, ITGB6
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strated a 1.65-fold increase in expression of NFkβ in
irradiated samples relative to control samples (Figure 2).
The network with second highest score has the IL5
(interleukin 5) and HTT (huntingtin) as the nodalmolecules and are presented in Figure 4B. The third
highest scoring network is involved in the regulation of
reproductive system development and function with LH
(luteinizing hormone) and FSH (follicle stimulating
hormone) as the nodal molecule (Figure 5A) and the
Figure 3 Radiation-induced alterations in canonical pathways identified by Ingenuity Pathway Analysis. A) A total of 37 canonical
pathways were significantly upregulated (p<0.05 indicated by threshold line). B) A total of 7 canonical pathways were downregulated (p<0.05).
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(potassium inwardly-rectifying channel, subfamily J,
member 11) as the nodal molecule (Figure 5B). The fifth
pathway is involved in cell cycle and cell death and has
TP53 as the nodal molecule (Figure 6A). Importantly,
the sixth, seventh, and the eighth pathway networks
have IL1β (Figure 6B), tumor necrosis factor (TNF;
Figure 7A), and IL4/IFNγ (Figure 7B) respectively as
the nodal molecules. We also observed that angiotensin
receptor type 1 (AGTR1; Figure 8A) and ERBB2
(Figure 8B) are the nodal molecules in ninth and tenth
IPA network and has relevance to breast cancer. The
eleventh network with PI3K complex (Figure 9A) as its
nodal molecule and the twelfth pathway with p38 MAPK
(Figure 9B) as its nodal molecule are also known to
play important roles in breast cancer initiation and pro-
gression. Among the downregulated networks 4 had
scores ≥8 and the networks with score in descending
order have TGFβ (Figure 10A), PRKCβ (Figure 10B),
IFNγ (Figure 11A), and TNF (Figure 11B) as the nodal
molecules respectively and are involved in a variety ofTable 2 Few pathways were downregulated and fewer were i
Ingenuity Canonical Pathways -log(
Fcγ receptor-mediated phagocytosis in macrophages
and monocytes
2.44
G-Protein coupled receptor signaling 1.92
Factors promoting cardiogenesis in vertebrates 1.64
Natural killer cell signaling 1.60
Mechanisms of viral exit from host cells 1.55
Leukocyte extravasation signaling 1.45
p70S6K signaling 1.32cellular functions from cell growth and proliferation
to lipid metabolism and small molecule biochemistry.
Genes, which were significantly associated with the path-
way networks in IPA were searched in the literature
for their roles in breast cancer and are compiled along
with relevant references in Table 5 for upregulated genes
and in Table 6 for downregulated genes. A total of
27 upregulated (ACHE [11], HSPA1L [12], NES [13],
P2RY2 [14], PLCG1 [15], PPARGC1A [16], PRKCQ [17],
SNTA1 [18], ALDOA [19], GNAO1 [20], SLC16A3
[21], TPI1 [22], ELL2 [23], CCNG1 [24], E2F6 [25],
ESRRG [26], MAPK12 [27], HSD17B7 [28], TACC2 [29],
DDX1 [30], MYH1 [31], UCP1 [32], PACSIN3 [33],
PGM1 [34], TLN2 [35], ADIPOR1 [36], PITX1 [37]) and
8 downregulated genes (CELSR2 [38], PRKCB [39], KIT
[40], MAP2 [41], TDGF1 [42], ELF1 [43], RUNX1 [44],
TYMS [45]) showed association with breast cancer.
Furthermore, the data files with the complete list of
the upregulated and downregulated networks are pre-
sented in Additional files 3 and 4, respectively, for fur-
ther reference.nvolved in cellular proliferation
p-value) Molecules
EZR, LYN, ACTG1, PRKCB
PRLHR, GPR173, PTGIR, GPRC5A, GLP2R, FZD3,
GPR113, ADCY7, CELSR2, PRKCB
FZD3, TDGF1, PRKCB
SH3BP2, Klra4 (includes others), PRKCB
ACTG1, PRKCB
EZR, MMP11, ACTG1, PRKCB
LYN, RPS6, PRKCB
Table 3 Upregulated networks with score ≥8 are presented
ID Molecules in Network Score Focus
Molecules
Top Functions
1 26sProteasome, ACHE, AChR, Akt, AQP4, BIN1, CAMK2A, CHRNA1,
Creb,ERK1/2, FRZB, HSPA1L, IDE, ISL1, KCNC1, KIAA0368, KIF1B,
MYOD1, MYOG, NES, NFkB (complex),NOL3, P2RY2, PDGF BB,
PGK1, PLCG1, PPARGC1A, PRKCQ, RAPSN, RNF217, RXRG,
S100B, SLC37A4, SNTA1, THPO
44 28 Cell Death, Neurological Disease,
Cellular Development
2 ALDOA, ARPP21, ATP1A1, ATP1B1, ATP2A2, ATP6V0E2, BCL6,
C15orf63, CIITA, ECSIT, FXYD4, Gapdh (includes others), Gm9790/
Higd1a, GNAO1, HNRNPUL1, HSP90AB1, HTT, IL5, LDLR, NAA15,
NDUFA12, PKM2, PMP22, POU3F1, RAB3A, RPH3A, SACS, SLC16A3,
SPI1, SQSTM1, SYN2, TPI1, TRAF6, TUBA3C/TUBA3D, XBP1
21 17 Genetic Disorder, Neurological Disease,
Skeletal and Muscular Disorders
3 ACTA1, ACTN1, AKAP6, ATP2B1, CDK16, CPE, ELL2, FSH, FYCO1, GK,
GOT1, GPCPD1, IPO13, KIDINS220, LBX1, Lh, LIF, MAP1LC3B,
NANOG, NOL3, PAX6, PCSK1N, PDE4D, PGK1, PHACTR2, PPFIA4,
PPP2R5B, PRKAR1A, PRKAR2A, PSMD1, Ryr1l, SNAP23, STX3,
TPM1 (includes EG:22003), VAMP8
19 16 Reproductive System Development and
Function, Cellular Development, Cellular
Growth and Proliferation
4 ABCC9, ALDOA, ATP1A1, CACNA1A, CACNA1B, CACNB1, CACNB4,
CDH15, CTNNB1, DLG4, GOT2, HTT, IDH2, IL5, KCNJ11, KRAS, LDHA,
LDHB, MYC, PCLO, PITX2, PRKCE, SCN1B, SCN2B, SLC25A4,
SLC27A1, SYT1, SYT2, TP53, TPI1, TRIO, UGP2, VDAC1
16 14 Molecular Transport, Genetic Disorder,
Carbohydrate Metabolism
5 AHR, APAF1, ATP1B2, BMI1, CAB39, CCNG1, CHEK2, CIITA, CREBBP,
E2F6, ESRRG, Estrogen Receptor, HIST1H1A, Hist2h4 (includes
others), HSP90AA1, MAPK12, MCM3, NFIC, Pcp4l1, PHC1,
PLA2G12A, PRNP, RAD51AP1, Rb, RING1, SFTPC, SMARCA4,
SMARCD3, STK11, STRADB, STUB1, Thymidine Kinase, TP53,
TUBA8, UBE2B
16 14 Cell Cycle, Cell Death, Hematological System
Development and Function
6 ATF3, B3GALT1,Calcineurin protein(s), Calmodulin, CCNA1, CIITA,
CISH, CORO6, CREB1, CYP8B1, F2, FEM1A, GDF1, Gsk3, GSTA5,
HSD17B7, HSPA8, IL1B, IL1R1, INSR, KCNQ5, Mapt, OPA3, PLCG1,
PMS1, PPARGC1A, PSEN1, RORA, SATB1, SERPINA3, SIX1,
SLC25A25, SOD1, TUBA4A, USP13
16 14 Cell Death, Neurological Disease,
Tissue Morphology
7 ACSL1, APOA4, BCL2, CITED2, CPT1B, CRYAB, E2F1, EYA4, FOXC2,
Fundc2, GSTA3, Ins1, ITGB6, KPNA3, Ldh, LEP, NEB, NEU2, NFKB1,
PCSK1, POU2F1, PPARGC1A, PPP1R3A, PTGES, PTGS2, SOX6, SP1,
SPTB, TMCC2, TNF, TNIK, TRAF2, TSPO, UCP3, ZFP36
16 14 Energy Production, Lipid Metabolism,
Small Molecule Biochemistry
8 APOA4, ATF3, CD3, CD80, CD86, CEBPB, CIITA, COL1A1, COX5A,
COX6B1, CPEB3, EFCAB6, ELAVL1, Gsk3, HELT, HSD11B1,
HSPB2, IDH3B, IFNG, IL4, IL1RN, IRF1, NEIL2, NEUROG1, NR3C2,
NRF1, POLR2A, Rac, TACC2, TCF7L2, TRAK1, TRAM2, USP2,
VLDLR, WWP2
14 13 Cellular Growth and Proliferation, Hematological
System Development and Function,
Tissue Development
9 ACTA1, ACTC1, AGTR1, C14orf166, CUL5, DCT, DDX1, DMPK,
DOT1L, EIF1AY, ENO1, ENPP4, FXR1, FXYD1, FZD9, Histone h3,
HRASLS, JUN, MECP2, MLLT3, MYH1, MYH2, MYH4, PABPC4,
RELN, SCNN1A, SGK1, STAU1, SYNCRIP, TCF4, THOC4, UCP1,
UQCRC1, YWHAZ, YY1
14 13 Cellular Function and Maintenance,
Molecular Transport, Cellular Assembly
and Organization
10 ABHD5, ADAM12, ADCK3, ADM, CALCRL, CD40LG, DOK7, ENDOG,
ERBB2, FILIP1, FLNA, G6pd2, GNB2L1, HIF1A, Hsp70, Hsp90,
HSP90AA1, IGF1R, ITGB1, KDM3A, MUSK, NR3C1, NRG1 (includes
EG:112400), PACSIN3, PAK1, PGM1, PLIN5, PRKCE, PSEN1, Rac,
RAMP1, SRC, STUB1, TLN2, TTN
11 11 Cell Death, Cell-To-Cell Signaling and Interaction,
Nervous System Development and Function
11 ADAM10, ADIPOR1, ADRA1B, CCND2, CCND3, COX7A1, CXCL10,
CXCL12, CYP11A1, CYP7A1, DMD, DTNA, DUSP26, FSHB, HIPK3,
HSF4, ITGB4, LCK, MAPK3, MAPRE3, MET, Mlc, NFKB2, NR5A1, PI3K
(complex), PIN1, PITX1, PLEC, PRKCZ, RAC1, Ras, SOX9, SYNC,
TCEA3, THRB
10 10 Cancer, Tissue Development, Embryonic
Development
12 ABCB4, AGER, AIMP2, CD2, CD28, CD40, CD59, CD86, CD40LG,
DISC1, DNM2, DYRK1B, FGFR1, GRB2, GRB14, HGF, IL2, IL12
(complex), JAK1, JAK2, MET, P38 MAPK, PDE4A, PDGFA, PDGFRB,
PIK3C2B, PLCG1, PTPN2, ASA1, SH2B3, Sos, SQSTM1, WAS,
ZAP70, ZFP106
8 9 Cellular Movement, Cell Death, Immune Cell
Trafficking
Highlighted genes are from the microarray dataset.
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Table 4 Downregulated networks with score ≥8 are presented
ID Molecules in Network Score Focus
Molecules
Top Functions
1 AGTR1, ARHGAP17, BAMBI, BARD1, BCL9, BRCA1, BRCC3, BRE,
CELSR2, FURIN, GLP2R, Gp49a/Lilrb4, HNRNPF, Hsd3b4
(includes others), IFIT2, IL12 (complex), ITGB1, JUN, mir-31,
Ms4a4b (includes others), MYD88, NAB2, NR3C1, PLCG1, PLXNB1,
PRKCB, RPS3A, RRAD, SEMA4D, SERPINB5, ST6GAL1, Talin, TGFB1,
TIAM1, TRAF3
26 16 Cell Morphology, Cellular Growth and Proliferation,
Hematological System Development and Function
2 ACPP, ACTG1, Actin, ADCY7, AKAP12, Akt, CAMK2B, DEFA1
(includes others), DGAT1, DHCR7, ERK1/2, EZR, FSH, GPRC5A,
GRIN1, HSD17B1, KIT, LAT2, Lh, LYN, MAP2, MAP2K2, MME,
MS4A2, Myosin, p85 (pik3r), PIK3AP1, PRKAR2B, PRKCB, SC4MOL,
SH3BP2, SLC6A3, TDGF1, TYRO3, UNC119
24 15 Cellular Compromise, Inflammatory Response,
Cell Signaling
3 AHR, B4GALNT1, BAZ1A, C1orf38, C5AR1, CD1D, ELF1, GHRH,
HDAC1, HIPK2, IFNA1/IFNA13, IFNG,IL4, INSM2, Lyz1/Lyz2, MAFB,
MMP11, MTA3, NEUROD1, Nuclear factor 1, OAS1, OAS2, PCSK1,
PCSK2, PPP4C, PPP5C, RB1, Rb, Runx1, SIN3B, SLC17A2, TFCP2,
TNFSF11, TP53, TYMS
24 15 Tissue Morphology, Cancer, Gene Expression
4 ACSL1, ADAM17, APOBEC3B, CASP7, CHSY3, CLMN, FDFT1, FDPS,
HLA-C, HMGCR, HSF1, HSPA1A/HSPA1B, IDI1, Klra4 (includes others),
LSS, NR1H3, PPP1R15A, RAI14, RALGPS2, RBL1, RPS6, SCNN1A,
SCNN1B, SCNN1G, SQLE, SREBF2, SYMPK, TNF, TP73, TSC2, WSB1,
WT1, YWHAG, YY1, ZNF267
18 12 Lipid Metabolism, Small Molecule Biochemistry,
Vitamin and Mineral Metabolism
Highlighted genes are from the microarray dataset.
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Mammary gland is sensitive to the carcinogenic actions
of radiation and epidemiological data strongly correlates
radiation exposure and breast cancer [1,2]. Here we
demonstrate that exposure of 6 to 8 week old female
mice to 2 Gy of γ radiation, a dose relevant to fractio-
nated radiotherapy, induced long-term gene expression
changes in the mammary glands. These changes are
associated with molecular pathways that have the poten-
tial to enhance the chance of malignant transformation.
We show that even after two months, a significantFigure 4 IPA identified two top signaling networks with genes involv
development network with NFkB as the nodal molecule. At least 12 (ACHE
S100B, and SNTA1) genes from this upregulated network are associated wi
is genetic disorder, neurological disease, skeletal and muscular disorders an
are known to be involved in cancer.number of genes remain perturbed and that the majo-
rity of them are upregulated. Broadly, these genes
are categorized into two major interdependent cellular
functions – proliferation and metabolism. Upregulation
of proliferative functions supported by induction of
adaptive energy producing pathways is also observed in
cancer cells [46]. Cancer, described as a chronic and
multifactorial disease, was not observed in these mice
within the study duration of 2 month. However, we did
observe alterations in signaling pathways that may be
considered potential carcinogenic precursors events.ed in carcinogenesis. A) The first network is cellular growth and
, HSPA1L, MYOD1, NES, NOL3, P2RY2, PGK1, PLCG1, PPARGC1A, PRKCQ,
th initiation and progression of human cancer. B) The second network
d at least 4 upregulated genes (ALDOA, GNAO1, SLC16A3, and TPI1)
Figure 5 Upregulation of cellular proliferation and metabolic pathways involved in neoplasia. A) The third upregulated network involves
reproductive system development and function, cellular development, cellular growth and proliferation and upregulation of at least one gene
(LBX1) has been associated with cellular transformation. B) The fourth upregulated network involves molecular transport, genetic disorder,
carbohydrate metabolism and at least 5 (ALDOA, LDHB, SLC16A3, TPI1, VDAC1) genes are related to carcinogenesis.
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genes from the data set and literature indicates that at
least 12 (ACHE, HSPA1L, MYOD1, NES, NOL3, P2RY2,
PGK1, PLCG1, PPARGC1A, PRKCQ, S100B, and SNTA1)
of them are involved in human cancer (genes relevant
to breast cancer are presented with relevant references
in Tables 5 and 6). Indeed, dysregulation of ACHE,
HSPA1L, NES, P2RY2, PLCG1, PPARGC1A, PRKCQ,
S100B, and SNTA1 genes have been implicated in breast
cancer progression and metastasis due to higher prolifera-
tion and increase cell migration (Tables 5 and 6). Cellular
metabolism and transportation related genes (ALDOA,
SLC16A3, TPI1, LDHB, KCNQ5, and PGM1), which are
implicated in human cancer, also remained upregulatedFigure 6 Cell cycle and cell death related pathways were upregulated
hematological system development as well as estrogen signaling such as C
know to regulate cell death, neurological disease, and tissue morphology.even 2-month after radiation exposure. Importantly, in-
duction of glycolytic enzymes like aldolase A (ALDOA),
lactate dehydrogenase (LDH), triosephosphate isomerase
1 (TPI1), and phosphoglucomutase 1 (PGM1), we believe,
is supporting cellular growth and development resulting
from upregulated proliferative signaling pathways. It has
been proposed that in a ‘Reverse Warburg Effect’ the
glycolytic pathway is upregulated in stromal cells generat-
ing pyruvate/lactate, which can then be utilized by adja-
cent epithelial cells for oxidative phosphorylation in
mitochondria [22]. Indeed, upregulation of ‘oxidative
phosphorylation’ and ‘mitochondrial dysfunction’ are the
two top canonical pathways observed in the IPA and are
reported to be associated with breast cancer [47]. While. A) The fifth upregulated network is involved in cell cycle, cell death,
CNG1, E2F6, and ESRRG. B) The molecules in the sixth network are
Figure 7 Two networks were associated with energy production and cell proliferation. A) Major functions associated with this network
are energy production, lipid metabolism, and small molecule biochemistry, and has a score of 16. B) The eighth network had a score of 14
and major functions associated with this network are cellular growth and proliferation, hematological system development and function,
and tissue development.
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http://www.ro-journal.com/content/7/1/205stromal cell niche is known to play important roles in
mammary gland carcinogenesis, we are yet to determine
whether there are differential alterations of gene expres-
sion in stromal vs. epithelial cells and would require
separate microarray analysis of stromal and epithelial
compartment in mammary glands. However, considered
along with the fact that in a whole boy irradiated mice
all the tissue compartments are exposed to radiation,
our results led us to speculate that differential altera-
tions of gene expression in stromal vs. epithelial cells
could occur in mammary gland to promote radiation
carcinogenesis and is supportive of what has been
reported in the literature [48,49]. Interestingly, bothFigure 8 Cell-to-cell signaling and molecular transport related to carc
network is associated with cellular function and maintenance, molecular tra
microarray data set were associated with this pathway and identified cell d
development and function as major functions.ALDOA and SLC16A3 are also suggested to be hypoxia
responsive and is upregulated in hypoxic breast cancer
with poor outcome. SLC16A3 is known to allow efflux
of lactate [21], which we believe is produced in excess
due to radiation-induced upregulation of glycolytic
enzymes. Increased glycolysis may have served as a trig-
ger for increased mitochondrial oxidative metabolism
observed in our results, and could lead to oxidative
stress as has been indicated by upregulation of canon-
ical pathways involved in ‘mitochondrial dysfunction’
and ‘production of nitric oxide and reactive oxygen spe-
cies in macrophages’. Interestingly, we also observed
upregulation of UCP1 (uncoupling protein 1), a memberinogenesis were upregulated. A) With a score of 14 this pathway
nsport, cellular assembly and organization. B) Eleven genes from the
eath, cell-to-cell signaling and interaction, nervous system
Figure 9 Cancer and cell death related pathways were upregulated. A) Genes in this pathway are involved in cancer, tissue development,
and embryonic development. B) The twelfth network had a score of 8 and 9 genes from the data set are associated with the network which is
involved in cellular movement, cell death, and immune cell trafficking.
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tory chain events from ATP production. UPC1 is
known to limit reactive oxygen species (ROS) produc-
tion, which could result in oxidative stress below apop-
totic threshold, and enhance cellular survival in the
presence of irreversible injury to respiration [32,50]. The
presence of radiation-induced mitochondrial dysfunction
and consequent oxidative injury to cells are further ex-
emplified by the upregulation of ENDOG, which has
been shown to be involved in cell death in the absence
of caspases [51].
Previously, we reported that exposure to 2 Gy radi-
ation led to persistent increase in estrogen levels
in serum and estrogen receptors in mammary glands at
2- and 12-month after radiation exposure and wasFigure 10 The downregulated networks may accelerate cellular trans
molecule and downregulation of at least 8 genes (ARHGAP17, BAMBI, BCL9
carcinogenesis. B) The second downregulated network has 6 genes (ACPP,
transformation.associated with activation of PI3K-Akt proliferative path-
ways [50]. Microarray data showing upregulation of 17β
hydroxysteroid dehydrogenase 7 (HSD17B7), an enzyme
involved in conversion of weakly estrogenic estrone
to biologically active estradiol in mammary glands, is
reported to be induced by high serum estradiol [52]
and is in agreement with our earlier observations of
increased serum estradiol after radiation [50]. While
systemic estradiol mediates its effects in mammary gland
via ERα, higher expression of HSD17B7 could provide
a ‘positive feed-forward’ mechanism for enhanced tissue
estradiol level [28] and could explain activation of cellu-
lar proliferative signals observed by us [50]. Upregula-
tion of estrogen-related receptor γ (ESRRG), which
is induced by estrogen to enhance cell proliferation,formation. A) The top downregulated network has TGFβ as the nodal
, BRCC3, CELSR2, NAB2, PRKCB, SEMA4D) in the network facilitates
GPRC5A, KIT, LYN, MAP2, and TDGF1) which may paly a role in cellular
Figure 11 Balancing promotion and inhibition of cell proliferation in the downregulated networks. A) Although 1 gene (GHRH) involved
in cell proliferation is downregulated in the third network, we observed downregulation of at least 4 key genes (ELF1, MTA3, RUNX1, and TYMS)
related to tumor suppressor function. B) The fourth downregulated network with a significant score of 18 has TNF as the nodal molecule and
downregulation of at least 2 genes (APOBEC3B, CHSY3) are known to promote carcinogenesis.
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array data and our previous results. Importantly, even
2-month after exposure to 2 Gy radiation a high number
of transcripts involved in cellular growth and develop-
ment including strongly mitogenic MAPK12 remain sig-
nificantly upregulated and are presented in Table 5.
Along with upregulation of genes involved in cellular
growth and development, we also observed that a num-
ber of genes with tumor suppressor function (GPRC5A,
ELF1, NAB2, Sema4D, ACPP, MAP2, RUNX1) persist-
ently remained downregulated in response to radiation
exposure further tilting the balance in favor of trans-
formation (Table 6) [43,53-58]. In contrast, a few genes
(TDGF1, GHRH, and BCL9) reported to be involved in
promoting cell proliferation are downregulated which
highlights the fact that cellular transformation is a multi-
stage process with a sustained tug of war between tumor
suppressor and tumor promoter. An important observa-
tion of our study was the downregulation of BRCC3
(BRCA1/BRCA2-containing complex, subunit 3), a pro-
tein known to play key a role in the repair of DNA dam-
age through its E3 ubiquitin ligase activity on the repair
factors [59] and may predispose the mammary gland
cells to misrepair and genomic instability. A number of
other downregulated genes positively affecting cellular
growth and proliferation have been observed in our
study and are listed in Table 6.
Molecular pathway networks identified by IPA allowed
us to understand how genes in our data sets spatially re-
late to oncogenic precursor events relevant to breast
cancer. The top-scoring pathway has NFkβ and Akt
(Figure 4A) as the central molecules and both are known
to be involved in breast carcinogenesis [60,61]. Anotherhigh scoring upregulated network identified ERBB2, an
important membrane bound receptor tyrosine kinase, as
the nodal molecule (Figure 8B) and is known to cross-
talk with NFkβ and PI3K-Akt to promote breast cancer
[62]. One of the important observations in our study
was the recognition of inflammation related factors in
the IPA network and a number of pathway showed IL-5
(Figure 4B), IL-1β (Figure 6B), TNF (Figure 7A), IL-4,
and INFγ (Figure 7B) as the central molecules highlight-
ing an already existing relationship between inflamma-
tion and breast cancer [63,64]. Reproductive hormones
LH and FSH are the central molecules in an upregulated
pathway network (Figure 5A) and are known to regulate
estrogen [65], which is strongly associated with risk of
developing breast cancer [66]. Indeed, in an earlier
study, we have shown that exposure to a radiation dose
(2 Gy) used in the current study significantly increased
serum estrogen level, urinary oncogenic estrogen metab-
olite level, mammary gland estrogen receptor α (ERα)
level, and cellular proliferation in mice [50]. Estrogen
has also been reported to influence TGFβ activity nega-
tively [67], and interestingly our downregulated data sets
mapped to a pathway, which has TGFβ as the nodal
molecule (Figure 10A). In our earlier study, we focused
on exploring one pathway, the PI3K-Akt pathway, in
relation to increased estrogen and ERα and showed that
radiation not only upregulated PI3K and Akt activity
but also induced their downstream effectors leading
to increased mammary gland cell proliferation deter-
mined by phospho-histone H3 staining [50]. Current
microarray based complete gene expression study after
radiation exposure not only showed upregulation of add-
itional pathways already discussed but also showed
Table 5 Genes from upregulated networks: A number of genes from the data set are associated with breast cancer
Gene Full name Role in breast cancer quoted from literature
ACHE Acetylcholinesterase “Tumor size was significantly higher when the ACHE gene was amplified
in breast cancer.” [11].
HSPA1L heat shock 70kDa protein 1-like “. . ...HSPA1L and HSPA2 could represent potential biomarkers to follow up
the effectiveness of 17AAG in breast cancer” [12].
NES Nestin “Among the breast cancer subtypes, nestin is highly expressed in basal
breast cancer subtype” [13].
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 “P2Y2 receptor-mediated modulation of estrogen-induced proliferation of
breast cancer cells” [14].
PLCG1 phospholipase C, gamma 1 “Phospholipase Cgamma1 is required for metastasis development and
progression” [15].
PPARGC1A peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha
“Associations of genetic variants in the estrogen receptor coactivators
PPARGC1A, PPARGC1B and EP300 with familial breast cancer” [16].
PRKCQ protein kinase C, theta “PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice” [17].
SNTA1 syntrophin, alpha 1 “. . ...significant increase in expression of SNTA1 protein compared with
the normal tissue was observed in breast carcinoma samples” [18].
ALDOA Aldolase A “. . .hypoxia-responsive; prognostic significance in breast cancer” [19].
GNAO1 guanine nucleotide binding protein (G protein),
alpha activating activity polypeptide O
“GNAO1 (Gαo) gene was identified in breast carcinomas and shown to
promote oncogenic transformation when introduced into cells” [20].
SLC16A3 solute carrier family 16, member 3 “Expression of SLC16A3 gene is higher in breast cancer distant metastasis. . ..” [21].
TPI1 triosephosphate isomerase 1 “Glycolytic cancer associated fibroblasts promote breast cancer tumor
growth, without a measurable increase in angiogenesis: evidence for
stromal-epithelial metabolic coupling” [22].
ELL2 elongation factor, RNA polymerase II, 2 ELL2 is a Breast Cancer Antioestrogen Resistance (BCAR) 1 gene which
control anti-oestrogen-resistant cell growth resistance (BCAR) [23].
CCNG1 cyclin G1 “We have identified cyclin G as being overexpressed in breast and prostate
cancer cells” [24].
E2F6 E2F transcription factor 6 “E2F6 represses transcription of the brca1, ctip, art27, hp1α, and the rbap48
genes. . ..” [25].
ESRRG Estrogen-related receptor γ “Estrogen-related receptor γ modulates cell proliferation and estrogen
signaling in breast cancer & ERRγ mRNA was up-regulated dose-
dependently by estrogen. . ..” [26].
MAPK12 mitogen-activated protein kinase 12. Also known
as ERK3; ERK6; SAPK3; PRKM12; SAPK-3; P38GAMMA
“. . .elevated expression of p38γ is associated with lower overall survival of
patients with breast cancer” [27].
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 The stimulation of HSD17B7 expression by estradiol provides a powerful
feed-forward mechanism for estradiol biosynthesis in breast cancer cells [28].
TACC2 transforming, acidic coiled-coil containing protein 2 “This suggests that increased TACC2 may mediate an oncogenic effect
on breast cancer cells and indicates that TACC2 may be a potential
therapeutic target” [29].
DDX1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 “Here, we identify DDX1 RNA overexpression as an independent prognostic
marker for early recurrence in primary breast cancer. . .. . .” [30].
MYH1 myosin, heavy chain 1, skeletal muscle, adult Recently, MYH1 encoding skeletal muscle myosin heavy polypeptide 1 and MYH9
encoding non-muscle myosin heavy chain type A, were identified as candidate
breast cancer genes in systematic analyses of the breast cancer genome [31].
UCP1 uncoupling protein 1 (mitochondrial) We conclude that UCP1 is up-regulated in breast cancer cell lines and
primary breast as well as other tumors [32].
PACSIN3 Protein kinase C and casein kinase substrate in
neurons protein 3
“New targets for breast cancer treatment were identified such as ZONAB,
PACSIN3, MRP8 and SUMO1, which have human homologues” [33].
PGM1 phosphoglucomutase 1 “This gene has been identified as one of the ER status markers in the
diagnosis and prognosis of breast cancer patients. . ...” [34].
TLN2 talin 2 “Serum estradiol levels associated with specific gene expression patterns
in normal breast tissue and in breast carcinomas. . .. . .” [35].
ADIPOR1 adiponectin receptor 1 “Variants of the Adiponectin and Adiponectin Receptor 1 Genes and Breast
Cancer Risk. . .” [36].
PITX1 paired-like homeodomain 1 “The estrogen-regulated transcription factor PITX1 coordinates gene-specific
regulation by estrogen receptor-alpha in breast cancer cells. . .” [37].
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Table 6 Genes from downregulated network
Gene Full name Role in cancer quoted from literature
CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 “Celsr2 was down-regulated in one cell line and in 7% of breast cancers” [38].
PRKCB protein kinase C, beta PRKCB has been observed to be downregulated in estrogen receptor negative
breast cancer [39].
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog. Also known as C-Kit; CD117
Loss of c-kit expression has been reported in 80-90% of breast cancer specimens,
suggesting a possible role in the development of tumors [40].
MAP2 microtubule-associated protein 2 “Elevation of MAP2 in breast cancer cell lines led to increased paclitaxel
sensitivity” [41].
TDGF1 teratocarcinoma-derived growth factor 1.
Also known as CR; CRGF; CRIPTO
“Overexpression of human Cripto-1 in transgenic mice delays mammary gland
development and differentiation and induces mammary tumorigenesis” [42].
ELF1 E74-like factor 1 “All of the mouse and most human mammary tumors also displayed decreased
expression of genes known to inhibit cell proliferation, including NFKBIA (IKBalpha),
GADD45B, and CDKN1A (p21); transcription-related genes such as CEBP, JUN, JUNB,
and ELF1;. . ...” [43].
RUNX1 runt-related transcription factor 1 “Furthermore, we found that RUNX1 expression was reduced in high-grade primary
breast tumors compared to low/mid-grade tumors” [44].
TYMS thymidylate synthetase “Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast
cancer: a case–control study” [45].
A number of genes identified with the downregulated networks are associated with breast cancer.
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having TP53 (Figure 6A), AGTR1 (Figure 8A), P38-
MAPK and PLCG1 (Figure 9B), PI3K complex and
MAPK3 (Figure 9A) as central molecule. The molecular
pathways, which IPA identified to be significantly asso-
ciated with the genes from the microarray data sets have
been implicated in human cancer including breast
cancer (Tables 5 and 6) and provide evidence towards
carcinogenic potential of therapeutic radiation exposure.
Conclusions
Exposure to diagnostic and therapeutic radiation has
increased considerably over time [3,68,69] and know-
ledge of the molecular pathways that remain perturbed
long-term after radiation exposure could inform us to
devise strategies to tackle the carcinogenic potential of
radiation. Taken together the microarray data presented
here not only correlate with our earlier observations on
long-term effects of radiation exposure on mammary
gland pathophysiology, but they also further expand on
the persistently perturbed molecular networks with po-
tential for transformation after exposure to a clinically
relevant radiation dose.
Additional files
Additional file 1: All the upregulated canonical pathways mapped
by Ingenuity Pathway Analysis are presented. The colored (blue)
pathways have p-value <0.05.
Additional file 2: All the downregulated canonical pathways
mapped by Ingenuity Pathway Analysis are presented. The colored
(blue) pathways have p-value <0.05.
Additional file 3: Complete list of upregulated signaling networks
generated by Ingenuity Pathway Analysis are presented. Highlighted
(bold) genes are from the microarray dataset.Additional file 4: Complete list of downregulated signaling
networks generated by Ingenuity Pathway Analysis are presented.
Highlighted (bold) genes are from the microarray dataset.
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